This topic contains a solution. Click here to go to the answer

Author Question: For the best therapeutic effect after a myocardial infarction (MI), thrombolytics should be ... (Read 34 times)

audragclark

  • Hero Member
  • *****
  • Posts: 579
For the best therapeutic effect after a myocardial infarction (MI), thrombolytics should be administered within the first 3 hours (ideally 30 minutes) of presentation of symptoms.
 
  Studies have shown that thrombolytic therapy, however, can be of benefit up to how many hours after the initial presentation of symptoms of MI?
  a. 6 hours c. 10 hours
  b. 8 hours d. 12 hours

Question 2

What percentage of patients with angina pectoris will have simultaneous dyspnea, caused by transient increase in pulmonary venous pressures that accompany ventricular stiffening during an episode of myocardial ischemia?
 
  a. About 20 c. About 50
  b. About 30 d. Almost all



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

wilsonbho

  • Sr. Member
  • ****
  • Posts: 322
Answer to Question 1

D

Answer to Question 2

B




audragclark

  • Member
  • Posts: 579
Reply 2 on: Jul 22, 2018
Excellent


nathang24

  • Member
  • Posts: 314
Reply 3 on: Yesterday
:D TYSM

 

Did you know?

This year, an estimated 1.4 million Americans will have a new or recurrent heart attack.

Did you know?

The top five reasons that children stay home from school are as follows: colds, stomach flu (gastroenteritis), ear infection (otitis media), pink eye (conjunctivitis), and sore throat.

Did you know?

Signs of depression include feeling sad most of the time for 2 weeks or longer; loss of interest in things normally enjoyed; lack of energy; sleep and appetite disturbances; weight changes; feelings of hopelessness, helplessness, or worthlessness; an inability to make decisions; and thoughts of death and suicide.

Did you know?

There are 60,000 miles of blood vessels in every adult human.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library